

Texas: Prior authorization updates for medications

Texas Health and Human Services (HHSC) has updated prior authorization requirements and clinical criteria for 2 medications. Beginning Nov. 24, 2025, UnitedHealthcare Community Plan of Texas will follow the updates outlined below.

Clinical criteria and authorization guidelines	Updates
Wegovy® (semaglutide)	<ul style="list-style-type: none"> • Added criteria for metabolic dysfunction-associated steatohepatitis (MASH) diagnosis as approved by the DUR Board • Removed check for pancreatitis and gastroparesis as approved by the DUR Board • Updated the lookback for medullary thyroid cancer (MTC) and multiple endocrine neoplasia syndrome type 2 (MEN2) to 730 days as approved by the DUR Board • Added Zepbound to the GLP-1 agonists supporting table • Removed Bydureon from the GLP-1 agonists supporting table — product discontinued
Zepbound® (tirzepatide)	<ul style="list-style-type: none"> • Removed check for gastroparesis as requested by the DUR Board • Updated the lookback for history of medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia syndrome type 2 (MEN 2) to 730 days as requested by the DUR Board

These changes apply to UnitedHealthcare Community Plan of Texas CHIP, STAR, STAR Kids and STAR+PLUS plans, and align with the Texas HHSC Vendor Drug Program's mandatory prior authorization requirements.

Questions? We're here to help.

Connect with us through chat 24/7 in the [UnitedHealthcare Provider Portal](#).